Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 22;26(1):220.
doi: 10.1186/s13063-025-08932-5.

Hyperbaric oxygen therapy for ulcerative colitis patients hospitalized for moderate to severe flares (HBOT-UC): study protocol for a multi-center, randomized, double-blind, sham-controlled trial

Lauren B Bonner  1 , Charlotte Sadler  2 , Peter Lindholm  2 , Denise M Scholtens  3 , Parambir S Dulai  4 ; HBOT-UC Consortium
Collaborators, Affiliations

Hyperbaric oxygen therapy for ulcerative colitis patients hospitalized for moderate to severe flares (HBOT-UC): study protocol for a multi-center, randomized, double-blind, sham-controlled trial

Lauren B Bonner et al. Trials. .

Abstract

Background: Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis. Hyperbaric oxygen therapy involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. It reduces systemic and local inflammation and up-regulates hypoxia response pathways, making it an attractive therapeutic option. In this trial we aim to confirm the treatment benefits of hyperbaric oxygen therapy for hospitalized ulcerative colitis patients and assess the long-term durability of treatment effect.

Methods: This prospective, double-masked, multicenter, 1:1 randomized, sham-controlled trial will enroll 126 participants with known or newly diagnosed ulcerative colitis hospitalized for an acute moderate to severe flare. Participants will be randomized to either hyperbaric oxygen therapy with steroids or sham air with steroids. The trial will involve a 5-day intervention period followed by a 12-month observational period with a 90-day standard of care visit and 12-month telephone visit. The primary outcome measure is clinical response defined as complete resolution of rectal bleeding and improvement in stool frequency, without need for in-hospital biologics, small molecules, or colectomy by study day 5. Secondary endpoints include additional key patient-reported outcomes and histo-endoscopic measures of disease activity.

Discussion: Novel and effective treatments are needed for this population to optimize disease outcomes while minimizing treatment-related risks. Demonstrating the ability of hyperbaric oxygen therapy to improve clinical response to steroids and avoid in-hospital rescue therapy has the potential to change the management of hospitalized ulcerative colitis flares.

Trial registration: ClinicalTrials.gov NCT05987852. Registered on August 14, 2023.

Keywords: Hyperbaric oxygen therapy; Randomized trial; Study protocol; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate {24}: The protocol was approved by Advarra, serving as the single IRB. Written informed consent to participate will be obtained from all participants, or their legally authorized representatives if applicable. Consent for publication {32}: Not applicable. Informed consent materials will be made available by the corresponding author upon request. Competing interests {28}: The authors have none to disclose.

Figures

Fig. 1
Fig. 1
HBOT-UC study schematic
See this image and copyright information in PMC

References

    1. Ma C, Smith MK, Guizzetti L, et al. Assessing national trends and disparities in ambulatory, emergency department, and inpatient visits for inflammatory bowel disease in the United States (2005–2016). Clin Gastroenterol Hepatol 2020; 18: 2500–2509.e2501. 20200125. 10.1016/j.cgh.2020.01.023. - PMC - PubMed
    1. Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol 2018; 16: 343–356.e343. 20170616. 10.1016/j.cgh.2017.06.016. - PMC - PubMed
    1. Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67(237–243):20170104. 10.1136/gutjnl-2016-313060. - PubMed
    1. Nguyen NH, Koola J, Dulai PS, et al. Rate of risk factors for and interventions to reduce hospital readmission in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2020; 18: 1939–1948.e1937. 20190827. 10.1016/j.cgh.2019.08.042. - PMC - PubMed
    1. Ordás I, Domènech E, Mañosa M, et al. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989–2013): A Nationwide Multicenter Study. Am J Gastroenterol. 2017;112(1709–1718):20170704. 10.1038/ajg.2017.180. - PubMed

Publication types

Associated data